Latest Articles

Publication Date
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors - The Manila Times

Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors The Manila Times

Published: Dec. 10, 2025, 12:40 p.m.
Molecular profiling of endometrial cancer in Martinique reveals frequent CCNE1 amplification in poor prognosis tumors - Nature

Molecular profiling of endometrial cancer in Martinique reveals frequent CCNE1 amplification in poor prognosis tumors Nature

Published: Nov. 19, 2025, 2:27 p.m.
Machine Learning Model Using CT Radiomics Achieves High Accuracy in Differentiating Malignant and Benign Endometrial Tumors - geneonline.com

Machine Learning Model Using CT Radiomics Achieves High Accuracy in Differentiating Malignant and Benign Endometrial Tumors geneonline.com

Published: Nov. 4, 2025, 1:32 p.m.
AI Radiomics Accurately Differentiates Endometrial Tumors - Bioengineer.org

AI Radiomics Accurately Differentiates Endometrial Tumors Bioengineer.org

Published: Nov. 4, 2025, 12:27 p.m.
AI Radiomics Accurately Differentiates Endometrial Tumors - BIOENGINEER.ORG

AI Radiomics Accurately Differentiates Endometrial Tumors BIOENGINEER.ORG

Published: Nov. 4, 2025, 12:27 p.m.
CT radiomics-based explainable machine learning model for accurate differentiation of malignant and benign endometrial tumors: a two-center study - BioMedical Engineering OnLine

CT radiomics-based explainable machine learning model for accurate differentiation of malignant and benign endometrial tumors: a two-center study BioMedical Engineering OnLine

Published: Nov. 4, 2025, 11:50 a.m.
Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors - The Manila Times

Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors The Manila Times

Published: Oct. 24, 2025, 3:57 p.m.
Correction: Endometrial cancer (EC) derived G3BP1 overexpression and mutant promote EC tumorigenesis and metastasis via SPOP/ERα axis - Cell Communication and Signaling

Correction: Endometrial cancer (EC) derived G3BP1 overexpression and mutant promote EC tumorigenesis and metastasis via SPOP/ERα axis Cell Communication and Signaling

Published: Oct. 24, 2025, 12:50 p.m.
Roche axes 4 Chugai solid tumor assets in early-phase clearout - Fierce Biotech

Roche axes 4 Chugai solid tumor assets in early-phase clearout Fierce Biotech

Published: Oct. 23, 2025, 8:53 a.m.
Roche axes 4 Chugai solid tumor assets in early-phase clear-out - Fierce Biotech

Roche axes 4 Chugai solid tumor assets in early-phase clear-out Fierce Biotech

Published: Oct. 23, 2025, 8:53 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!